相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Survival after neoadjuvant therapy with trastuzumab-lapatinib and chemotherapy in patients with HER2-positive early breast cancer: a meta-analysis of randomized trials
V Guarneri et al.
ESMO OPEN (2022)
VP6-2022: Adjuvant pertuzumab and trastuzumab in patients with early HER-2 positive breast cancer in APHINITY: 8.4 years' follow-up
S. Loibl et al.
ANNALS OF ONCOLOGY (2022)
Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection plus chemotherapy in HER2-positive early breast cancer (FeDeriCa): a randomised, open-label, multicentre, non-inferiority, phase 3 study
Antoinette R. Tan et al.
LANCET ONCOLOGY (2021)
Updated Standardized Definitions for Efficacy End Points (STEEP) in Adjuvant Breast Cancer Clinical Trials: STEEP Version 2.0
Sara M. Tolaney et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Chemotherapy de-escalation using an 18F-FDG-PET-based pathological response-adapted strategy in patients with HER2-positive early breast cancer (PHERGain): a multicentre, randomised, open-label, non-comparative, phase 2 trial
Jose Manuel Perez-Garcia et al.
LANCET ONCOLOGY (2021)
Original Research Preference for the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer (PHranceSCa): A randomised, open-label phase II study
Joyce O'Shaughnessy et al.
EUROPEAN JOURNAL OF CANCER (2021)
Efficacy, Safety, and Tolerability of Pertuzumab, Trastuzumab, and Docetaxel for Patients With Early or Locally Advanced ERBB2-Positive Breast Cancer in Asia The PEONY Phase 3 Randomized Clinical Trial
Zhimin Shao et al.
JAMA ONCOLOGY (2020)
HER2-enriched subtype and pathological complete response in HER2-positive breast cancer: A systematic review and meta-analysis
Francesco Schettini et al.
CANCER TREATMENT REVIEWS (2020)
What Is the Real Impact of Estrogen Receptor Status on the Prognosis and Treatment of HER2-Positive Early Breast Cancer?
Mariana Brandao et al.
CLINICAL CANCER RESEARCH (2020)
Three-year follow-up of neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2-blockade for HER2-positive breast cancer (TRAIN-2): A randomized phase III trial.
Anna van der Voort et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Local-regional recurrence in women with small node-negative, HER2-positive breast cancer: results from a prospective multi-institutional study (the APT trial)
Jennifer R. Bellon et al.
BREAST CANCER RESEARCH AND TREATMENT (2019)
Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
F. Cardoso et al.
ANNALS OF ONCOLOGY (2019)
Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer
G. von Minckwitz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Long-term efficacy analysis of the randomised, phase II TRYPHAENA cardiac safety study: Evaluating pertuzumab and trastuzumab plus standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer
Andreas Schneeweiss et al.
EUROPEAN JOURNAL OF CANCER (2018)
Neoadjuvant treatment with trastuzumab and pertuzumab plus palbociclib and fulvestrant in HER2-positive, ER-positive breast cancer (NA-PHER2): an exploratory, open-label, phase 2 study
Luca Gianni et al.
LANCET ONCOLOGY (2018)
Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2): a multicentre, open-label, randomised, phase 3 trial
Mette S. van Ramshorst et al.
LANCET ONCOLOGY (2018)
Pertuzumab, trastuzumab, and standard anthracycline- and taxane-based chemotherapy for the neoadjuvant treatment of patients with HER2-positive localized breast cancer (BERENICE): a phase II, open-label, multicenter, multinational cardiac safety study
S. M. Swain et al.
ANNALS OF ONCOLOGY (2018)
HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer (PAMELA): an open-label, single-group, multicentre, phase 2 trial
Antonio Llombart-Cussac et al.
LANCET ONCOLOGY (2017)
Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer
Gunter von Minckwitz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
De-escalation strategies in HER2-positive early breast cancer (EBC): final analysis of the WSG-ADAPT HER2+/HR- phase II trial: efficacy, safety, and predictive markers for 12 weeks of neoadjuvant dual blockade with trastuzumab and pertuzumab ± weekly paclitaxel
U. A. Nitz et al.
ANNALS OF ONCOLOGY (2017)
Molecular Heterogeneity and Response to Neoadjuvant Human Epidermal Growth Factor Receptor 2 Targeting in CALGB 40601, a Randomized Phase III Trial of Paclitaxel Plus Trastuzumab With or Without Lapatinib
Lisa A. Carey et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial
Luca Gianni et al.
LANCET ONCOLOGY (2016)
Adjuvant Paclitaxel and Trastuzumab for Node-Negative, HER2-Positive Breast Cancer
Sara M. Tolaney et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Molecular Features and Survival Outcomes of the Intrinsic Subtypes Within HER2-Positive Breast Cancer
Aleix Prat et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2014)
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
Patricia Cortazar et al.
LANCET (2014)
2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial
Aron Goldhirsch et al.
LANCET (2013)
Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial
Andre Robidoux et al.
LANCET ONCOLOGY (2013)
Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial
Jose Baselga et al.
LANCET (2012)
Long-term toxic effects of adjuvant chemotherapy in breast cancer
H. A. Azim et al.
ANNALS OF ONCOLOGY (2011)
Supervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes
Joel S. Parker et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Measurement of residual breast cancer burden to predict survival after Neoadjuvant chemotherapy
W. Fraser Symmans et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Adjuvant trastuzumab in the treatment of her-2-positive early breast cancer: a meta-analysis of published randomized trials
Gustavo A. Viani et al.
BMC CANCER (2007)
Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment:: The M77001 study group
M Marty et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
分享论文
